Literature DB >> 17221252

[Revision of the recommendations of the Commission on Pharmacotherapy of the German Society for Rheumatology. Recommendations for supportive therapy for Sjögren's syndrome].

A Gause1.   

Abstract

For the treatment of sicca symptoms as a manifestation of Sjögren's syndrome there are various tear substitutes as well as artificial saliva. The appropriate substances are discussed in this article. In addition to reducing symptoms, some of the effective compounds offer the advantage of infection prophylaxis in the form of better lubrication of the mucous membranes in the airways as well as reduced susceptibility to candidiasis. The presence of bromhexin in the catalogue of the statutory medical insurance agencies is recommended. Certain of the available drugs are still only available in foreign pharmacies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17221252     DOI: 10.1007/s00393-006-0133-5

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  11 in total

1.  Candida albicans levels in patients with Sjögren's syndrome before and after long-term use of pilocarpine hydrochloride: a pilot study.

Authors:  N L Rhodus; W Liljemark; C Bloomquist; J Bereuter
Journal:  Quintessence Int       Date:  1998-11       Impact factor: 1.677

2.  Cevimeline for the treatment of xerostomia in patients with Sjögren syndrome: a randomized trial.

Authors:  Rose S Fife; Walter F Chase; Robin K Dore; Craig W Wiesenhutter; Peter B Lockhart; Elizabeth Tindall; James Y Suen
Journal:  Arch Intern Med       Date:  2002-06-10

3.  A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren's syndrome patients with xerostomia and keratoconjunctivitis sicca.

Authors:  Dianne Petrone; John J Condemi; Rose Fife; Oscar Gluck; Stanley Cohen; Paul Dalgin
Journal:  Arthritis Rheum       Date:  2002-03

4.  Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group.

Authors:  K Sall; O D Stevenson; T K Mundorf; B L Reis
Journal:  Ophthalmology       Date:  2000-04       Impact factor: 12.079

5.  Sjörgren's syndrome treated with bromhexine: a randomised clinical study.

Authors:  K Frost-Larsen; H Isager; R Manthorpe
Journal:  Br Med J       Date:  1978-06-17

6.  Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease.

Authors:  B A Noble; R S K Loh; S MacLennan; K Pesudovs; A Reynolds; L R Bridges; J Burr; O Stewart; S Quereshi
Journal:  Br J Ophthalmol       Date:  2004-05       Impact factor: 4.638

7.  Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome: a randomized, placebo-controlled, fixed-dose, multicenter trial. P92-01 Study Group.

Authors:  F B Vivino; I Al-Hashimi; Z Khan; F G LeVeque; P L Salisbury; T K Tran-Johnson; C C Muscoplat; M Trivedi; B Goldlust; S C Gallagher
Journal:  Arch Intern Med       Date:  1999-01-25

8.  Bromhexine treatment of Sjögren's syndrome: effect on lacrimal and salivary secretion, and on proteins in tear fluid and saliva.

Authors:  R Manthorpe; K Frost-Larsen; L Høj; H Isager; J U Prause
Journal:  Scand J Rheumatol       Date:  1981       Impact factor: 3.641

9.  The clinical effects of electrostimulation on salivary function of Sjögren's syndrome patients. A placebo controlled study.

Authors:  N Talal; J H Quinn; T E Daniels
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

10.  Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study.

Authors:  N Tsifetaki; G Kitsos; C A Paschides; Y Alamanos; V Eftaxias; P V Voulgari; K Psilas; A A Drosos
Journal:  Ann Rheum Dis       Date:  2003-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.